Acipimox

Acipimox Struktur
51037-30-0
CAS-Nr.
51037-30-0
Bezeichnung:
Acipimox
Englisch Name:
Acipimox
Synonyma:
K-9321;Olbetam;Olbemox;ACIPIMOX;Acipimox (K-9321);Acyclovir therapy;AcipiMox-13C2,15N2;Acipimox USP/EP/BP;Methylpyrazine Oxide;Acipimox Solution, 100ppm
CBNumber:
CB2490951
Summenformel:
C6H6N2O3
Molgewicht:
154.12
MOL-Datei:
51037-30-0.mol

Acipimox Eigenschaften

Schmelzpunkt:
177-180 °C
Siedepunkt:
539.0±45.0 °C(Predicted)
Dichte
1.44±0.1 g/cm3(Predicted)
storage temp. 
Inert atmosphere,2-8°C
Löslichkeit
Soluble in methanol, water (100 mM), DMSO (100 mM), ethanol (<1 mg/ml at 25° C), and 1 M NH4OH (1 mg/ml).
Aggregatzustand
Solid
pka
2.80±0.10(Predicted)
Farbe
Yellow
Merck 
14,111
InChIKey
DJQOOSBJCLSSEY-UHFFFAOYSA-N
CAS Datenbank
51037-30-0(CAS DataBase Reference)
EPA chemische Informationen
Pyrazinecarboxylic acid, 5-methyl-, 4-oxide (51037-30-0)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher Xi
R-Sätze: 36
S-Sätze: 26
WGK Germany  3
RTECS-Nr. UQ2453000
HS Code  2933.99.8290
Toxizität LD50 orally in mice: 3500 mg/kg (Ambrogi)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
Sicherheit
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Acipimox Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R36:Reizt die Augen.

S-Sätze Betriebsanweisung:

S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.

Beschreibung

Acipimox is a nicotinic acid derivate that structurally related to nicotinic acid. Like nicotinic acid, lowers lipids effectively, but unlike nicotinic acid, acipimox is longer acting and therefore much less prone to produce free fatty acid rebounding. It is usually employed in man in the therapy of hypertriglyceridemia. In addition to its lipid lowering activity, it produces a beneficial elevation of the anti-atherogenic high density lipoprotein subfraction, HDL2. Acipimox is recommended as a lipid-lowering agent to treat hyperlipidemia in patients with noninsulin dependent diabetes mellitus.

Chemische Eigenschaften

Yellow Solid

Charakteristisch

The advantages of acipimox to niacin are as follows:
Longer duration of inhibition of hormone-sensitive lipase than niacin.
A lower dose (250 mg BD or TDS) of acipimox is required to lower lipid levels and better tolerability with fewer side effects than niacin.
Acipimox increases insulin sensitivity, while niacin causes insulin resistance. Thus, acipimox has a favorable role in patients with dyslipidemia and diabetes, whereas niacin is contraindicated in diabetes.
Acipimox has adjuvant role in the management of PCOD and increases tissuesensitivity to GH, whereas niacin does not.

Verwenden

Acipimox is a long-acting antilipemic agent and used for the treatment of hyperlipoproteinemias, in particular hypertriglyceridemias, and as adjunctive therapy for affecting cholesterol metabolism.

synthetische

Synthesis of acipimox: Under cooling and stirring, 78 g of maleic anhydride was dissolved in a solution of 60 ml of chloroform, and 40 ml of 30% hydrogen peroxide was added. After 2 h, 4.8 g of 5-Methyl-2-pyrazinecarboxylic acid was added, and the temperature was kept at 0-5 °C for 2 d. The maleic acid was filtered off. Concentrate to a small volume, add ethyl acetate, and filter to obtain 1.1 g of acipimox, the melting point of which is 178-180 °C.

benefits

1. Act on the liver and adipose tissue, inhibit the lipolysis of adipose tissue, thereby reducing plasma total cholesterol, triglyceride, low-density lipoprotein, and very low-density lipoprotein.
2. Increase high-density lipoprotein in plasma, which is beneficial to the transport and clearance of cholesterol.
3. Increase liver glycogen synthesis and lower blood sugar levels. Asimimox can be used as the first-choice lipid-lowering drug for the treatment of various hyperlipidemias, especially for those with diabetes mellitus with hyperlipidemia.

Biologische Aktivität

Acipimox, also known as olbemox, is a nicotinic acid analog. It functions as an anti-lipolytic drug and vasodilator. Acipimox may be used in various metabolic studies involving insulin and ghrelin. It lowers total cholesterol and total triglycerides, which helps in the treatment of hyperlipidemia.

Clinical Use

Acipimox was introduced in Europe to treat hyperlipidemia in 1985. Acipimox is a weak agonist of GPR109A with micromolar binding and functional activity.Like niacin, acipimox raises HDL-C and triggers vasodilation in humans.However, it remains unclear whether acipimox causes mild hyperglycemia as is observed with niacin.

Nebenwirkungen

Adverse effects include flushing (associated with Prostaglandin D2), rash, palpitations, and GI disturbances (nausea, dyspepsia, diarrhoea and upper abdominal pain) . Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.

Arzneimittelwechselwirkung

Potentially hazardous interactions with other drugs. It can be combined with powerful hypolipidemic drugs such as fenofibrate and lovastatin to enhance the efficacy and reduce the dose and side effects of the drug. Acyclolimus can improve the efficacy of hypoglycemic drugs, so it is necessary to reduce the dose of hypoglycemic drugs and adjust the dose according to the patient's blood sugar. In antioxidant therapy, it can be used in combination with probucol.

Mode of action

Acipimox is a nicotinic acid derivative (methyl-pyrazine-carboxylic-acid-oxide) that acts on the niacin receptor (GPR109A).The mechanism of action is similar to niacin (inhibition of hormone-sensitive lipase). However,the inhibition of hormone-sensitive lipase by acipimox is remarkably longer (9-12 h) than that of niacin (3 h). Similar to niacin, acipimox also lowers the levels of lp(a).

Einzelnachweise

[1] Ana T.M.G. Santomauro, Guenther Boden, Maria E.R. Silva, Dalva M. Rocha, Rosa F. Santos, Mileni J.M. Ursich, Paula G. Strassmann and Bernardo L. Wajchenberg, Overnight Lowering of Free Fatty Acids With Acipimox Improves Insulin Resistance and Glucose Tolerance in Obese Diabetic and Nondiabetic Subjects, Diabetes, 1999, vol. 48, 1836-1841
[2] K. C. Shih, C. F. Kwok, C. M. Hwu, L. C. Hsiao, S. H. Li, Y. F. Liu, L. T. Ho, Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control, Diabetes Research and Clinical Practice, 1997, vol. 36, 113-119

Acipimox Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Acipimox Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 299)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Baoji Guokang Bio-Technology Co., Ltd.
0917-3909592 13892490616
gksales1@gk-bio.com China 9315 58
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
sales@hbmojin.com China 12829 58
Hebei Chuanghai Biotechnology Co,.LTD
+86-13131129325
sales1@chuanghaibio.com China 5893 58
Zibo Hangyu Biotechnology Development Co., Ltd
+86-0533-2185556 +8617865335152
Mandy@hangyubiotech.com China 10986 58
Hangzhou Hyper Chemicals Limited
+86-0086-57187702781 +8613675893055
info@hyper-chem.com China 295 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618092446649
sarah@tnjone.com China 1143 58
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806
sales@capot.com China 29791 60
Jinan Shengqi pharmaceutical Co,Ltd
86+18663751872
christine@shengqipharm.com CHINA 491 58
Xiamen AmoyChem Co., Ltd
+86-86-5926051114 +8618959220845
sales@amoychem.com China 6383 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63687 58

51037-30-0(Acipimox)Verwandte Suche:


  • 4-Oxo-5-Methyl-2-Pyrazine-carboxylic Acid
  • 4-Oxide-5-Methylpyrazine-2-CarboxylicAcid
  • 2-Carboxy-5-methylpyrazine 4-oxide, 5-Methylpyrazinecarboxylic acid 4-oxide
  • K-9321
  • Olbemox
  • Olbetam
  • 5-Carboxy-2-methylpyrazine 1-oxide
  • Acipimox (5-Methylpyrazinecarboxylic acid 4-oxide)
  • 2-Pyrazinecarboxylic acid, 5-methyl-, 4-oxide
  • 5-Methyl-4-oxide-2-pyrazinecarboxylicacid
  • 5-METHYLPYRAZINECARBOXYLICACID4-OXIDE
  • 5-METHYLPYRANZINECARBOXYLIC ACID 4-OXIDE
  • 6-Methyl-1-oxo-1$l^{5},4-pyrazine-3-carboxylic acid
  • AcipiMox-13C2,15N2
  • 2-Carboxy-5-methylpyrazine 4-oxide
  • ACIPIMOX
  • 5-methyl-2-pyrazinecarboxylicaci4-oxide
  • 5-methyl-2-pyrazinecarboxylicacid4-oxide
  • 5-methylpyrazine-2-carboxylic acid 4-oxide
  • Acipimox (K-9321)
  • Acipimox USP/EP/BP
  • 5-Methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
  • Methylpyrazine Oxide
  • 5-Methylpyrazine-2-carboxylicAcid4-Oxide>
  • Acipimox Solution, 100ppm
  • Acipimox Solution, 1000ppm
  • 5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid
  • Acyclovir therapy
  • Acipimox Powder USP Standard
  • 5-methyl-4-oxidopyrazin-4-ium-2-carboxylicaci
  • 5-Methylpyrazine-2-carboxylic Acid 4-Oxide, ≥ 98.0%
  • 51037-30-0
  • OLBEMOX
  • Pharmaceuticals
  • Pyrazine
  • Heterocycles
  • Intermediates & Fine Chemicals
Copyright 2019 © ChemicalBook. All rights reserved